Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by mcarter4on Sep 30, 2003 4:25pm
286 Views
Post# 6475450

RE: Bought deal (not pp): the perils

RE: Bought deal (not pp): the perilsFrom CBC Underwriters lose millions on CAE share issue Last Updated Tue, 30 Sep 2003 11:27:33 MONTREAL - The underwriting syndicate that helped flight simulator maker CAE raise $175 million through a recent offering of shares now finds itself holding shares that are worth far less than what they paid for them. The investment banks underwriting the offering bought the entire 26.6 million shares CAE was selling. The purchase was a "bought deal". That's where one or two underwriters buy an entire issue and then resell the shares to the public. The share offering, which closed Tuesday, was priced at $6.58 a share. At the time the offering was announced on Sept. 11, that seemed like a good deal, as CAE shares closed on Sept. 11 at $6.72. FROM Sept. 26, 2003: CAE shares fall on loss of $800 million U.S. Army contract But last Friday, CAE revealed that it had lost out on an $800-million US training contract with the U.S. Army. CAE shares fell dramatically on that news. In Tuesday morning trading, CAE shares were at $5.13. At $1.45 a share below the offering price, that means the underwriters have a paper loss of $38.57 million on the 26.6 million shares they've bought, because they cannot sell them above the current market price. At this point, the underwriters (who haven't been named) have little choice but to park the shares in their own corporate accounts and wait for the stock price to recover to at least $6.58. Under terms of the original offering, the underwriters have the option of buying an additional 2.66 million shares at $6.58 each until October 30. It's a safe bet that this option will not be exercised unless CAE shares stage a dramatic recovery in the next month. Written by CBC News Online staff
Bullboard Posts